The global cancer biologics market size accounted for USD 102.01 billion in 2023 and is projected to rake around USD 214.59 billion by 2033, growing at a CAGR of 7.12% from 2024 to 2033.
Key Points
- North America dominated the cancer biologics market in 2023
- Asia Pacific is expected to grow steadily in the market during the forecast period.
- The monoclonal antibodies segment dominated the market by drug class in 2023.
- The cancer growth inhibitors segment is expected to grow to the highest CAGR in the market by application during the forecast period.
- The blood cancer segment dominated the market by application in 2023.
- The lung cancer segment is expected to grow to the highest CAGR in the market by application during the forecast period.
- In 2023, the hospital segment dominated the market by end-use.
- The cancer center segment is expected to grow to the highest CAGR in the market by end-use during the forecast period.
The Cancer Biologics Market has witnessed substantial growth in recent years, driven by several key factors. Biologics, which are drugs derived from living organisms, have gained significant attention in the treatment of cancer due to their targeted approach and reduced side effects compared to traditional chemotherapy. The market for cancer biologics is expected to continue its upward trajectory, fueled by increasing prevalence of cancer worldwide, advancements in biotechnology, and growing demand for personalized medicine.
Get a Sample: https://www.precedenceresearch.com/sample/4005
One of the primary growth factors driving the Cancer Biologics Market is the rising incidence of cancer globally. With cancer being one of the leading causes of mortality worldwide, there is a pressing need for effective and targeted treatment options. Biologics offer a promising avenue in this regard, as they can specifically target cancer cells while sparing healthy tissues, thereby improving treatment outcomes and quality of life for patients.
Regionally, North America holds a significant share in the Cancer Biologics Market, owing to factors such as high healthcare expenditure, advanced infrastructure, and strong research and development activities in biotechnology. The presence of key market players and favorable regulatory environment further contribute to the dominance of North America in the market. However, Asia Pacific is poised to witness rapid growth in the coming years, driven by increasing investments in healthcare infrastructure, rising awareness about cancer treatment options, and expanding patient pool.
Cancer Biologics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 7.12% |
| Global Market Size in 2023 | USD 102.01 Billion |
| Global Market Size by 2033 | USD 214.59 Billion |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Drug Class, By Applications, and By End-use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Cancer Biologics Market Dynamics
Several drivers are propelling the growth of the Cancer Biologics Market. Technological advancements in biotechnology have led to the development of novel biologics with enhanced efficacy and reduced toxicity. Additionally, the shift towards personalized medicine and targeted therapies has spurred demand for biologics, as they offer the potential for tailored treatment based on individual patient characteristics and molecular profiles.
Moreover, the growing acceptance of immunotherapy as a standard treatment option for various types of cancer has bolstered the demand for cancer biologics. Immunotherapies harness the body’s immune system to fight cancer, offering a promising approach for patients who do not respond to traditional treatments. Key players in the Cancer Biologics Market are increasingly focusing on developing innovative immunotherapies to address unmet medical needs and expand their market presence.
Despite the promising growth prospects, the Cancer Biologics Market is not without its challenges. One of the primary challenges is the high cost associated with biologics, which can limit access to treatment, particularly in developing countries. Additionally, the complex manufacturing processes involved in producing biologics pose logistical and regulatory hurdles, leading to longer development timelines and higher production costs.
Furthermore, the emergence of biosimilars, which are highly similar versions of approved biologic drugs, presents both opportunities and challenges for the Cancer Biologics Market. While biosimilars offer potential cost savings and increased affordability for patients, they also intensify competition and exert downward pressure on pricing, thereby impacting the profit margins of original biologic manufacturers.
Read Also: Urinalysis Market Size to Attain USD 3.65 Billion by 2033
Recent Developments
- Dr. Reddy’s Laboratories declared in March 2024 that Versavo® (bevacizumab) would be available in the UK. Avastin’s biosimilar Versavo is effective against multiple cancer types, such as advanced non-squamous non-small cell lung cancer, metastatic colorectal cancer, ovarian cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and metastatic breast cancer.
- BioNTech and Duality Biologics declared in January 2024 that a Phase III trial of a medication for breast cancer has begun. BioNTech and Duality are conducting a Phase III trial to evaluate their antibody-drug conjugate in patients whose tumors have low levels of progesterone or estrogen and respond to these hormones. This corresponds to between 40% and 45% of patients with metastatic breast cancer who are on Herceptin for HER2.
- Angle, a liquid biopsy firm that provides diagnostic solutions for circulating tumor cells (CTCs) in drug development, research, and clinical oncology, announced in November 2023 that the Portrait PD-L1 test would be available for CTCs to assess PD-L1 protein expression.
- In April 2023, TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, announced its public launch and the closing of a $158 million Series B financing.
Cancer Biologics Market Companies
- Abbott
- Angel
- Amgen, Inc
- AstraZeneca
- BioNTech
- Bristol-Mayer Squibb Company
- Dr. Reddy’s Laboratories
- Duality Biologics
- Eli Lilly and Company
- F.Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- Glenmark Pharmaceuticals Ltd
- GSK plc.
- Ichnos Sciences Inc
- Johnson & Johnson Services, Inc
- Pfizer, Inc
- TFC Therapeutics
Segments Covered in the Report
By Drug Class
- Monoclonal Antibodies
- Naked Monoclonal Antibodies
- Conjugated Monoclonal Antibodies
- Bispecific Monoclonal Antibodies
- Cancer Growth Inhibitors
- Tyrosine Kinase Inhibitor
- Mtor Inhibitors
- Proteasome Inhibitors
- Others
- Vaccines
- Preventive Vaccines
- Therapeutic Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Others
By Applications
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Others
By End use
- Hospitals
- Cancer Center
- Academics & Research Institutes
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.dailytechbulletin.com/
Blog: https://www.autoindustrybulletin.com/
